Revision History

Researchers at Spain's National Cancer Research Centre (CNIO) have achieved complete elimination of pancreatic tumors in mice using a triple-drug combination targeting the KRAS pathway at three simultaneous points, with no tumor resistance developing for over 200 days. The breakthrough, published in PNAS, addresses the central challenge of pancreatic cancer treatment — drug resistance — and arrives amid a broader surge in KRAS-targeting therapies entering human clinical trials, though translating these preclinical results to patients remains years away.